Bruce R. Schackman, Ph.D. - Publications

Affiliations: 
2001 Harvard University, Cambridge, MA, United States 
Area:
Public Health

147 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Starbird LE, Gutkind S, Teixeira P, Murphy S, Aharonovich E, Zingman BS, Hasin D, Schackman BR. Economic Cost of the HealthCall Smartphone Intervention to Reduce Heavy Alcohol Drinking in Adults with HIV. Journal of Studies On Alcohol and Drugs. PMID 37449954 DOI: 10.15288/jsad.22-00377  0.304
2022 Martel-Laferrière V, Feaster DJ, Metsch LR, Schackman BR, Loignon C, Nosyk B, Tookes H, Behrends CN, Arruda N, Adigun O, Goyer ME, Kolber MA, Mary JF, Rodriguez AE, Yanez IG, et al. Correction: MHepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID. Trials. 23: 815. PMID 36167548 DOI: 10.1186/s13063-022-06724-9  0.303
2022 Gutkind S, Starbird LE, Murphy SM, Teixeira PA, Gooden LK, Matheson T, Feaster DJ, Jain MK, Masson CL, Perlman DC, Del Rio C, Metsch LR, Schackman BR. Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. Drug and Alcohol Dependence. 232: 109265. PMID 35042101 DOI: 10.1016/j.drugalcdep.2022.109265  0.349
2021 Zang X, Mah C, Linh Quan AM, Min JE, Armstrong WS, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Kirk GD, Marshall BD, Mehta SH, Metsch LR, Pandya A, Schackman BR, et al. Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum: A contrast of six US cities. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 34723929 DOI: 10.1097/QAI.0000000000002844  0.614
2021 Quan AML, Mah C, Krebs E, Zang X, Chen S, Althoff K, Armstrong W, Behrends CN, Dombrowski JC, Enns E, Feaster DJ, Gebo KA, Goedel WC, Golden M, Marshall BDL, ... ... Schackman BR, et al. Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. The Lancet. Hiv. PMID 34370977 DOI: 10.1016/S2352-3018(21)00147-8  0.581
2020 Behrends CN, Kapadia SN, Schackman BR, Frimpong JA. Addressing Barriers to On-site HIV and HCV Testing Services in Methadone Maintenance Treatment Programs in the United States: Findings From a National Multisite Qualitative Study. Journal of Public Health Management and Practice : Jphmp. PMID 33346582 DOI: 10.1097/PHH.0000000000001262  0.347
2020 Zang X, Krebs E, Chen S, Piske M, Armstrong WS, Behrends CN, Del Rio C, Feaster DJ, Marshall BDL, Mehta SH, Mermin J, Metsch LR, Schackman BR, Strathdee SA, Nosyk B. The potential epidemiological impact of COVID-19 on the HIV/AIDS epidemic and the cost-effectiveness of linked, opt-out HIV testing: A modeling study in six US cities. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33045723 DOI: 10.1093/cid/ciaa1547  0.399
2020 Jordan AE, Cleland CM, Wyka K, Schackman BR, Perlman DC, Nash D. Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. The Journal of Infectious Diseases. 222: S322-S334. PMID 32877567 DOI: 10.1093/Infdis/Jiz659  0.31
2020 Jordan AE, Cleland CM, Schackman BR, Wyka K, Perlman DC, Nash D. Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program. The Journal of Infectious Diseases. 222: S335-S345. PMID 32877560 DOI: 10.1093/Infdis/Jiz686  0.303
2020 Krebs E, Zang X, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Gebo KA, Marshall BDL, Mehta SH, Metsch LR, Pandya A, Schackman BR, Strathdee SA, et al. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. The Journal of Infectious Diseases. 222: S301-S311. PMID 32877548 DOI: 10.1093/Infdis/Jiaa130  0.651
2020 Zang X, Krebs E, Mah C, Min JE, Marshall BD, Feaster DJ, Schackman BR, Metsch LR, Strathdee SA, Behrends CN, Nosyk B. Can the 'Ending the HIV Epidemic' initiative transition the US towards HIV/AIDS epidemic control? Aids (London, England). PMID 32796216 DOI: 10.1097/Qad.0000000000002668  0.471
2020 Nosyk B, Weiner J, Krebs E, Zang X, Enns B, Behrends CN, Feaster DJ, Jalal H, Marshall BDL, Pandya A, Schackman BR, Meisel ZF. Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X20945308. PMID 32755285 DOI: 10.1177/0272989X20945308  0.467
2020 Schackman BR. The Value and Challenge of Frequent HIV Testing Among Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32730624 DOI: 10.1093/Cid/Ciaa1060  0.386
2020 Nosyk B, Krebs E, Zang X, Piske M, Enns B, Min JE, Behrends CN, Del Rio C, Feaster DJ, Golden M, Marshall BDL, Mehta SH, Meisel ZF, Metsch LR, Pandya A, ... Schackman BR, et al. 'Ending the Epidemic' will not happen without addressing racial/ethnic disparities in the US HIV epidemic. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32424416 DOI: 10.1093/Cid/Ciaa566  0.595
2020 Nosyk B, Zang X, Krebs E, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Golden M, Marshall BDL, Mehta SH, Metsch LR, Pandya A, Schackman BR, et al. Ending the HIV epidemic in the USA: an economic modelling study in six cities. The Lancet. Hiv. PMID 32145760 DOI: 10.1016/S2352-3018(20)30033-3  0.644
2020 Frimpong JA, Shiu-Yee K, Tross S, D'Aunno T, Perlman DC, Strauss SM, Schackman BR, Feaster DJ, Metsch LR. Bundling Rapid Human Immunodeficiency Virus and Hepatitis C Virus Testing to Increase Receipt of Test Results: A Randomized Trial. Medical Care. PMID 32040038 DOI: 10.1097/Mlr.0000000000001311  0.369
2020 Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR. Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City. Journal of Urban Health : Bulletin of the New York Academy of Medicine. PMID 32016914 DOI: 10.1007/S11524-020-00422-0  0.339
2020 Jordan AE, Perlman DC, Cleland CM, Wyka K, Schackman BR, Nash D. Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 124: 104285. PMID 32007842 DOI: 10.1016/J.Jcv.2020.104285  0.36
2019 Flash MJE, Garland WH, Martey EB, Schackman BR, Oksuzyan S, Scott JA, Jeng PJ, Rubio M, Losina E, Freedberg KA, Kulkarni SP, Hyle EP. Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County. Open Forum Infectious Diseases. 6: ofz537. PMID 31909083 DOI: 10.1093/Ofid/Ofz537  0.457
2019 Seo G, Joseph JMB, Confident N, Jean E, Louis B, Bell T, Riche RC, Belizaire ME, Rouzier V, Apollon A, Reif L, Rivera V, Abrams E, Bang H, Schackman B, et al. The FANMI ("my FAMILY" in Creole) study to evaluate community-based cohort care for adolescent and young women living with HIV in Haiti: protocol for a randomized controlled trial. Bmc Public Health. 19: 1749. PMID 31888569 DOI: 10.1186/S12889-019-8065-6  0.452
2019 Zang X, Krebs E, Min JE, Pandya A, Marshall BDL, Schackman BR, Behrends CN, Feaster DJ, Nosyk B. Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X19889356. PMID 31865849 DOI: 10.1177/0272989X19889356  0.628
2019 Ying R, Fekadu L, Schackman BR, Verguet S. Spatial Distribution and Characteristics of HIV Clusters in Ethiopia. Tropical Medicine & International Health : Tm & Ih. PMID 31808592 DOI: 10.1111/Tmi.13356  0.412
2019 Krebs E, Zang X, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Gebo KA, Golden M, Marshall BDL, Metsch LR, Schackman BR, Shoptaw S, Strathdee SA, et al. The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. Aids (London, England). PMID 31794521 DOI: 10.1097/Qad.0000000000002455  0.503
2019 Nosyk B, Zang X, Krebs E, Min JE, Behrends CN, Del Rio C, Dombrowski J, Feaster DJ, Golden M, Marshall BDL, Mehta SH, Metsch L, Schackman BR, Shoptaw S, Strathdee SA. Ending the epidemic in America will not happen if the status quo continues: modeled projections for HIV incidence in 6 US cities. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31609446 DOI: 10.1093/Cid/Ciz1015  0.411
2019 Behrends CN, Paone D, Nolan ML, Tuazon E, Murphy SM, Kapadia SN, Jeng PJ, Bayoumi AM, Kunins HV, Schackman BR. Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. Journal of Substance Abuse Treatment. 106: 79-88. PMID 31540615 DOI: 10.1016/J.Jsat.2019.08.010  0.313
2019 Zang X, Krebs E, Wang L, Marshall BDL, Granich R, Schackman BR, Montaner JSG, Nosyk B. Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. Pharmacoeconomics. PMID 31222521 DOI: 10.1007/S40273-019-00817-1  0.469
2019 McCrimmon T, Gilbert L, Hunt T, Terlikbayeva A, Wu E, Darisheva M, Primbetova S, Kuskulov A, Davis A, Dasgupta A, Schackman BR, Metsch LR, Feaster DJ, Baiserkin B, El-Bassel N. Improving HIV service delivery for people who inject drugs in Kazakhstan: study protocol for the Bridge stepped-wedge trial. Implementation Science : Is. 14: 62. PMID 31200757 DOI: 10.1186/S13012-019-0909-Z  0.488
2019 Krebs E, Enns B, Wang L, Zang X, Panagiotoglou D, Del Rio C, Dombrowski J, Feaster DJ, Golden M, Granich R, Marshall B, Mehta SH, Metsch L, Schackman BR, Strathdee SA, et al. Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. Plos One. 14: e0217559. PMID 31145752 DOI: 10.1371/Journal.Pone.0217559  0.459
2019 Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31095683 DOI: 10.1093/Cid/Ciz384  0.334
2019 Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. The International Journal On Drug Policy. PMID 31085063 DOI: 10.1016/J.Drugpo.2019.05.010  0.511
2019 Schackman BR, Jeng PJ, Flash MJE, Mejia M, Oksuzyan S, Scott JA, Freedberg KA, Kulkarni SP, Garland WH. Cost of an HIV Medical Care Coordination Program in Los Angeles County. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 30865169 DOI: 10.1097/Qai.0000000000001994  0.452
2019 Hood JE, Behrends CN, Irwin A, Schackman BR, Chan D, Hartfield K, Hess J, Banta-Green C, Whiteside L, Finegood B, Duchin J. The projected costs and benefits of a supervised injection facility in Seattle, WA, USA. The International Journal On Drug Policy. 67: 9-18. PMID 30802842 DOI: 10.1016/J.Drugpo.2018.12.015  0.314
2019 Nosyk B, Min JE, Zang X, Feaster DJ, Metsch L, Marshall BDL, Rio CD, Granich R, Schackman BR, Montaner JSG. Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic. Journal of the International Association of Providers of Aids Care. 18: 2325958218821962. PMID 30798657 DOI: 10.1177/2325958218821962  0.515
2019 McNeely J, Troxel AB, Kunins HV, Shelley D, Lee JD, Walley A, Weinstein ZM, Billings J, Davis NJ, Marcello RK, Schackman BR, Barron C, Bergmann L. Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. Addiction Science & Clinical Practice. 14: 5. PMID 30777122 DOI: 10.1186/S13722-019-0135-7  0.318
2019 Murphy S, McCollister K, Jeng P, Leff J, Lee J, Nunes E, Novo P, Rotrosen J, Schackman B. PMH20 COST-EFFECTIVENESS OF INCREASING THE EFFICIENCY OF THE DETOXIFICATION PROCESS PRIOR TO INITIATION OF EXTENDED-RELEASE NALTREXONE FOR THE TREATMENT OF OPIOID USE DISORDER Value in Health. 22: S683-S684. DOI: 10.1016/J.Jval.2019.09.1494  0.307
2018 Kapadia SN, Wu C, Mayer KH, Wilkin TJ, Amico KR, Landovitz RJ, Andrade A, Chen YQ, Chege W, McCauley M, Gulick RM, Schackman BR. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. Plos One. 13: e0206577. PMID 30586364 DOI: 10.1371/Journal.Pone.0206577  0.412
2018 Miclette MA, Leff JA, Cuan I, Samet JH, Saloner B, Mendell G, Bao Y, Ashburn MA, Bachhuber MA, Schackman BR, Polsky DE, Meisel ZF. Closing the gaps in opioid use disorder research, policy and practice: conference proceedings. Addiction Science & Clinical Practice. 13: 22. PMID 30424803 DOI: 10.1186/S13722-018-0123-3  0.357
2018 Bao Y, Wen K, Johnson P, Jeng PJ, Meisel ZF, Schackman BR. Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions. Health Affairs (Project Hope). 37: 1596-1604. PMID 30273045 DOI: 10.1377/Hlthaff.2018.0512  0.308
2018 McCollister KE, Yang X, Murphy SM, Leff JA, Kronmal RA, Crane HM, Chandler RK, Taxman FS, Feaster DJ, Metsch LR, Cunningham WE, Altice FL, Schackman BR. Criminal justice measures for economic data harmonization in substance use disorder research. Health & Justice. 6: 17. PMID 30242561 DOI: 10.1186/S40352-018-0073-6  0.349
2018 Behrends CN, Nugent AV, Des Jarlais DC, Frimpong JA, Perlman DC, Schackman BR. Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 29985266 DOI: 10.1097/Qai.0000000000001792  0.422
2018 Behrends CN, Eggman AA, Gutkind S, Bresnahan MP, Fluegge K, Laraque F, Litwin AH, Meissner P, Shukla SJ, Perumalswami PV, Weiss J, Wyatt BE, Schackman BR. A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination. Journal of Public Health Management and Practice : Jphmp. PMID 29975342 DOI: 10.1097/Phh.0000000000000806  0.337
2018 Kapadia SN, Johnston CD, Marks KM, Schackman BR, Martin EG. Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. Journal of Public Health Management and Practice : Jphmp. PMID 29927900 DOI: 10.1097/Phh.0000000000000829  0.323
2018 Panagiotoglou D, Olding M, Enns B, Feaster DJ, Del Rio C, Metsch LR, Granich RM, Strathdee SA, Marshall BDL, Golden MR, Shoptaw S, Schackman BR, Nosyk B. Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities. Aids and Behavior. PMID 29802550 DOI: 10.1007/S10461-018-2166-6  0.495
2018 Murphy SM, Leff JA, Linas BP, Morgan JR, McCollister K, Schackman BR. Implementation of a nationwide health economic consultation service to assist substance use researchers: Lessons learned. Substance Abuse. 1-19. PMID 29558284 DOI: 10.1080/08897077.2018.1449173  0.402
2018 Schackman BR, Gutkind S, Morgan JR, Leff JA, Behrends CN, Delucchi KL, McKnight C, Perlman DC, Masson CL, Linas BP. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. Drug and Alcohol Dependence. PMID 29477574 DOI: 10.1016/J.Drugalcdep.2017.11.031  0.352
2018 Akiyama MJ, Agyemang L, Arnsten JH, Heo M, Norton BL, Schackman BR, Linas BP, Litwin AH. Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. Bmc Infectious Diseases. 18: 74. PMID 29426304 DOI: 10.1186/S12879-018-2964-5  0.37
2018 Martin EG, Schackman BR. Treating and Preventing HIV with Generic Drugs - Barriers in the United States. The New England Journal of Medicine. 378: 316-319. PMID 29365306 DOI: 10.1056/Nejmp1710914  0.47
2018 Ying R, Fekadu L, Schackman BR, Verguet S. 862. Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters Open Forum Infectious Diseases. 5: S21-S21. DOI: 10.1093/Ofid/Ofy209.047  0.418
2017 Kapadia SN, Jeng PJ, Schackman BR, Bao Y. State Medicaid hepatitis C treatment eligibility criteria and use of direct acting antivirals. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29206910 DOI: 10.1093/Cid/Cix1062  0.313
2017 Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29020317 DOI: 10.1093/Cid/Cix798  0.334
2017 Hernández D, Castellón PC, Fernández Y, Torres-Cardona FA, Parish C, Gorshein D, Vargas Vidot J, Miranda de Leon S, Rodriguez A, Santana Bagur J, Feaster DJ, Schackman BR, Metsch LR. When "the Cure" Is the Risk: Understanding How Substance Use Affects HIV and HCV in a Layered Risk Environment in San Juan, Puerto Rico. Health Education & Behavior : the Official Publication of the Society For Public Health Education. 1090198117728547. PMID 28891344 DOI: 10.1177/1090198117728547  0.424
2017 McCollister K, Yang X, Sayed B, French MT, Leff JA, Schackman BR. Monetary conversion factors for economic evaluations of substance use disorders. Journal of Substance Abuse Treatment. 81: 25-34. PMID 28847452 DOI: 10.1016/J.Jsat.2017.07.008  0.36
2017 Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment. PMID 28733097 DOI: 10.1016/J.Jsat.2017.07.001  0.313
2017 Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infectious Diseases. 4: ofw266. PMID 28480259 DOI: 10.1093/Ofid/Ofw266  0.522
2017 Wen H, Schackman BR, Aden B, Bao Y. States With Prescription Drug Monitoring Mandates Saw A Reduction In Opioids Prescribed To Medicaid Enrollees. Health Affairs (Project Hope). 36: 733-741. PMID 28373340 DOI: 10.1377/Hlthaff.2016.1141  0.311
2017 Leff JA, Hernández D, Teixeira PA, Castellón PC, Feaster DJ, Rodriguez AE, Santana-Bagur JL, De León SM, Vidot JV, Metsch LR, Schackman BR. The structural and health policy environment for delivering integrated HIV and substance use disorder treatments in Puerto Rico. Bmc Health Services Research. 17: 232. PMID 28335754 DOI: 10.1186/S12913-017-2174-7  0.497
2017 Bray JW, Aden B, Eggman AA, Hellerstein L, Wittenberg E, Nosyk B, Stribling JC, Schackman BR. Quality of life as an outcome of opioid use disorder treatment: A systematic review. Journal of Substance Abuse Treatment. PMID 28190543 DOI: 10.1016/J.Jsat.2017.01.019  0.305
2017 Behrends CN, Frimpong JA, D’Aunno T, Pollack H, Schackman B, Friedmann P. The affordable care act and HIV/HCV testing in substance use disorder treatment programs Drug and Alcohol Dependence. 171: e17. DOI: 10.1016/J.Drugalcdep.2016.08.062  0.436
2016 Feaster DJ, Parish CL, Gooden L, Matheson T, Castellon PC, Duan R, Pan Y, Haynes LF, Schackman BR, Malotte CK, Mandler RN, Colfax GN, Metsch LR. Substance use and STI acquisition: Secondary analysis from the AWARE study. Drug and Alcohol Dependence. 169: 171-179. PMID 27837708 DOI: 10.1016/J.Drugalcdep.2016.10.027  0.406
2016 Bao Y, Pan Y, Taylor A, Radakrishnan S, Luo F, Pincus HA, Schackman BR. Prescription Drug Monitoring Programs Are Associated With Sustained Reductions In Opioid Prescribing By Physicians. Health Affairs (Project Hope). 35: 1045-1051. PMID 27269021 DOI: 10.1377/Hlthaff.2015.1673  0.303
2016 Frimpong JA, D'Aunno T, Perlman DC, Strauss SM, Mallow A, Hernandez D, Schackman BR, Feaster DJ, Metsch LR. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial. Trials. 17: 117. PMID 26936623 DOI: 10.1186/S13063-016-1225-4  0.468
2016 Schackman BR, Eggman AA, Leff JA, Braunlin M, Felsen UR, Fitzpatrick L, Telzak EE, El-Sadr W, Branson BM. Costs of Expanded Rapid HIV Testing in Four Emergency Departments. Public Health Reports (Washington, D.C. : 1974). 131: 71-81. PMID 26862232 DOI: 10.1177/00333549161310S109  0.477
2016 Pandya A, Eggman AA, Kamel H, Gupta A, Schackman BR, Sanelli PC. Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. Plos One. 11: e0148106. PMID 26840397 DOI: 10.1371/Journal.Pone.0148106  0.489
2015 Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. Hiv Clinical Trials. 1-12. PMID 26651525 DOI: 10.1080/15284336.2015.1123942  0.578
2015 Schackman BR, Haas DW, Park SS, Li XC, Freedberg KA. Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics. PMID 26607811 DOI: 10.2217/Pgs.15.142  0.468
2015 Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, Schackman BR. Short term health-related quality of life improvement during opioid agonist treatment. Drug and Alcohol Dependence. PMID 26511766 DOI: 10.1016/J.Drugalcdep.2015.10.009  0.312
2015 Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. Hiv Clinical Trials. 1945577115Y000000000. PMID 26365741 DOI: 10.1179/1945577115Y.0000000009  0.525
2015 Simon MS, Weiss D, Geevarughese A, Kratz MM, Cutler B, Gulick RM, Zucker JR, Varma JK, Schackman BR. Cost-Effectiveness of Meningococcal Vaccination among Men who Have Sex with Men in New York City. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 26334735 DOI: 10.1097/Qai.0000000000000822  0.393
2015 Aden B, Dunning A, Nosyk B, Wittenberg E, Bray JW, Schackman BR. Impact of Illicit Drug Use on Health-Related Quality of Life in Opioid-Dependent Patients Undergoing HIV Treatment. Journal of Acquired Immune Deficiency Syndromes (1999). 70: 304-10. PMID 26218410 DOI: 10.1097/Qai.0000000000000768  0.428
2015 Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, Des Jarlais DC. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. The International Journal On Drug Policy. 26: 1056-63. PMID 26050614 DOI: 10.1016/J.Drugpo.2015.04.015  0.356
2015 Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Annals of Internal Medicine. 162: 619-29. PMID 25820703 DOI: 10.7326/M14-1313  0.501
2015 Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E. The lifetime medical cost savings from preventing HIV in the United States. Medical Care. 53: 293-301. PMID 25710311 DOI: 10.1097/Mlr.0000000000000308  0.627
2015 Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E. The clinical role and cost-effectiveness of long-acting antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 60: 1102-10. PMID 25583979 DOI: 10.1093/Cid/Ciu1159  0.594
2015 Kimmel AD, Fitzgerald DW, Pape JW, Schackman BR. Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 35: 230-42. PMID 25331914 DOI: 10.1177/0272989X14551755  0.747
2015 Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (Abingdon, England). 110: 129-43. PMID 25291977 DOI: 10.1111/Add.12754  0.404
2015 Pandya A, Gupta A, Kamel H, Navi BB, Sanelli PC, Schackman BR. Carotid artery stenosis: cost-effectiveness of assessment of cerebrovascular reserve to guide treatment of asymptomatic patients. Radiology. 274: 455-63. PMID 25225841 DOI: 10.1148/Radiol.14140501  0.545
2015 Linas B, Morgan J, Pho M, Leff J, Schackman B, Assoumou S, Salomon J, Freedberg K, Kim A. P0798 : The cost-effectiveness of sofosbuvir- and simeprevirbased therapies for HCV genotype 1 infection Journal of Hepatology. 62: S633. DOI: 10.1016/S0168-8278(15)31001-1  0.319
2015 Hernández D, Fernández Y, Cardona FT, Castellon P, Vidot JV, Leon SMd, Feaster D, Schackman B, Rodriguez A, Santana J, Metsch L. Understanding drug use and the HIV cascade of care in San Juan, Puerto Rico Drug and Alcohol Dependence. 146: e141. DOI: 10.1016/J.Drugalcdep.2014.09.301  0.441
2014 Eggman AA, Feaster DJ, Leff JA, Golden MR, Castellon PC, Gooden L, Matheson T, Colfax GN, Metsch LR, Schackman BR. The cost of implementing rapid HIV testing in sexually transmitted disease clinics in the United States. Sexually Transmitted Diseases. 41: 545-50. PMID 25118967 DOI: 10.1097/Olq.0000000000000168  0.494
2014 Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. Plos One. 9: e97317. PMID 24842841 DOI: 10.1371/Journal.Pone.0097317  0.499
2014 Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. Aids (London, England). 28: 365-76. PMID 24670522 DOI: 10.1097/Qad.0000000000000093  0.58
2014 Simon MS, Leff JA, Pandya A, Cushing M, Shaz BH, Calfee DP, Schackman BR, Mushlin AI. Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. Transfusion. 54: 889-99. PMID 24252132 DOI: 10.1111/Trf.12492  0.505
2013 Metsch LR, Feaster DJ, Gooden L, Schackman BR, Matheson T, Das M, Golden MR, Huffaker S, Haynes LF, Tross S, Malotte CK, Douaihy A, Korthuis PT, Duffus WA, Henn S, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. Jama. 310: 1701-10. PMID 24150466 DOI: 10.1001/Jama.2013.280034  0.453
2013 Aden B, Nosyk B, Wittenberg E, Schackman BR. Health-Related Quality of Life in HIV-Infected and At-Risk Women: The Impact of Illicit Drug Use and Hepatitis C on a Community Preference Weighted Measure. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 34: 800-808. PMID 24106234 DOI: 10.1177/0272989X13507340  0.451
2013 Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 1607-17. PMID 24046302 DOI: 10.1093/Cid/Cit595  0.448
2013 Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JS. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Affairs (Project Hope). 32: 1462-9. PMID 23918492 DOI: 10.1377/Hlthaff.2012.0846  0.329
2013 Pati R, Lahuerta M, Elul B, Okamura M, Alvim MF, Schackman B, Bang H, Fernandes R, Assan A, Lima J, Nash D. Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy (ART) in Mozambique. Journal of the International Aids Society. 16: 18490. PMID 23755857 DOI: 10.7448/Ias.16.1.18490  0.379
2013 Martin EG, Meehan T, Schackman BR. AIDS Drug Assistance Programs: managers confront uncertainty and need to adapt as the Affordable Care Act kicks in. Health Affairs (Project Hope). 32: 1063-71. PMID 23733980 DOI: 10.1377/Hlthaff.2012.0123  0.328
2013 Mayer K, Gazzard B, Zuniga JM, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler SJ, Granich R, Horberg MA, McCormack S, Montaner JS, Rees H, ... Schackman B, et al. Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis. Journal of the International Association of Providers of Aids Care. 12: 208-16. PMID 23666450 DOI: 10.1177/2325957413475839  0.498
2013 Schackman BR. The value of HIV screening in the United States in the era of effective treatment. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 457-9. PMID 23635831 DOI: 10.1177/0272989X13486978  0.54
2013 Kimmel AD, Charles M, Deschamps MM, Severe P, Edwards AM, Johnson WD, Fitzgerald DW, Pape JW, Schackman BR. Lives saved by expanding HIV treatment availability in resource-limited settings: the example of Haiti. Journal of Acquired Immune Deficiency Syndromes (1999). 63: e40-8. PMID 23535289 DOI: 10.1097/Qai.0B013E3182918875  0.744
2013 Martin EG, Schackman BR. Updating the HIV-testing guidelines--a modest change with major consequences. The New England Journal of Medicine. 368: 884-6. PMID 23425132 DOI: 10.1056/Nejmp1214630  0.489
2013 Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Annals of Internal Medicine. 158: 84-92. PMID 23318310 DOI: 10.7326/0003-4819-158-2-201301150-00002  0.594
2013 Schackman BR, Haas DW, Becker JE, Berkowitz BK, Sax PE, Daar ES, Ribaudo HJ, Freedberg KA. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antiviral Therapy. 18: 399-408. PMID 23264445 DOI: 10.3851/Imp2500  0.433
2013 Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug and Alcohol Dependence. 128: 90-7. PMID 22971593 DOI: 10.1016/J.Drugalcdep.2012.08.009  0.492
2013 Martin EG, Strach P, Schackman BR. The state(s) of health: Federalism and the implementation of health reform in the context of HIV care Public Administration Review. 73. DOI: 10.1111/Puar.12072  0.482
2013 Kimmel AD, Schackman BR. Considerations for developing applied health policy models: The example of HIV treatment expansion in resource-limited settings International Series in Operations Research and Management Science. 190: 313-339. DOI: 10.1007/978-1-4614-6507-2_15  0.659
2012 Schackman BR, Eggman AA. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Current Opinion in Hiv and Aids. 7: 587-92. PMID 23076124 DOI: 10.1097/Coh.0B013E3283582C8B  0.505
2012 Martin EG, Schackman BR. What does U.S. health reform mean for HIV clinical care? Journal of Acquired Immune Deficiency Syndromes (1999). 60: 72-6. PMID 22517415 DOI: 10.1097/Qai.0B013E31824C0Dd4  0.459
2012 Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, Tross S, Kyle T, Gallup D, Kosinski AS, Douaihy A, Schackman BR, Das M, Lindblad R, Erickson S, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. American Journal of Public Health. 102: 1160-7. PMID 22515871 DOI: 10.2105/Ajph.2011.300460  0.454
2012 Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 279-90. PMID 22491339 DOI: 10.1093/Cid/Cis382  0.419
2012 Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. Hiv Clinical Trials. 13: 1-10. PMID 22306583 DOI: 10.1310/Hct1301-1  0.423
2012 Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care Journal of General Internal Medicine. 27: 669-676. PMID 22215271 DOI: 10.1007/S11606-011-1962-8  0.306
2012 Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, Paltiel AD, Freedberg KA, Yazdanpanah Y. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. Aids (London, England). 26: 45-56. PMID 22008655 DOI: 10.1097/Qad.0B013E32834Dce6E  0.443
2011 Koenig SP, Bang H, Severe P, Jean Juste MA, Ambroise A, Edwards A, Hippolyte J, Fitzgerald DW, McGreevy J, Riviere C, Marcelin S, Secours R, Johnson WD, Pape JW, Schackman BR. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. Plos Medicine. 8: e1001095. PMID 21949643 DOI: 10.1371/Journal.Pmed.1001095  0.455
2011 Tross S, Campbell AN, Calsyn DA, Metsch LR, Sorensen JL, Shoptaw S, Haynes L, Woody GE, Malow RM, Brown LS, Feaster DJ, Booth RE, Mandler RN, Masson C, Holmes BW, ... ... Schackman BR, et al. NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs. The American Journal of Drug and Alcohol Abuse. 37: 283-93. PMID 21854270 DOI: 10.3109/00952990.2011.596977  0.454
2011 Haynes LF, Korte JE, Holmes BE, Gooden L, Matheson T, Feaster DJ, Leff JA, Wilson L, Metsch LR, Schackman BR. HIV rapid testing in substance abuse treatment: implementation following a clinical trial. Evaluation and Program Planning. 34: 399-406. PMID 21367457 DOI: 10.1016/J.Evalprogplan.2011.02.007  0.454
2011 Schackman BR, Leff JA, Botsko M, Fiellin DA, Altice FL, Korthuis PT, Sohler N, Weiss L, Egan JE, Netherland J, Gass J, Finkelstein R. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation. Journal of Acquired Immune Deficiency Syndromes (1999). 56: S76-82. PMID 21317599 DOI: 10.1097/Qai.0B013E31820A9A66  0.492
2011 Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. Journal of Viral Hepatitis. 18: 506-12. PMID 20546501 DOI: 10.1111/J.1365-2893.2010.01325.X  0.498
2010 Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. Hiv Clinical Trials. 11: 248-59. PMID 21126955 DOI: 10.1310/Hct1105-248  0.423
2010 Schackman BR. Implementation science for the prevention and treatment of HIV/AIDS. Journal of Acquired Immune Deficiency Syndromes (1999). 55: S27-31. PMID 21045596 DOI: 10.1097/Qai.0B013E3181F9C1Da  0.43
2010 Martin EG, Paltiel AD, Walensky RP, Schackman BR. Expanded HIV screening in the United States: what will it cost government discretionary and entitlement programs? A budget impact analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 893-902. PMID 20950323 DOI: 10.1111/J.1524-4733.2010.00763.X  0.473
2010 Koenig SP, Schackman BR, Riviere C, Leger P, Charles M, Severe P, Lastimoso C, Colucci N, Pape JW, Fitzgerald DW. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 51: 600-8. PMID 20649436 DOI: 10.1086/655762  0.337
2010 Christopoulos KA, Schackman BR, Lee G, Green RA, Morrison EA. Results from a New York City emergency department rapid HIV testing program. Journal of Acquired Immune Deficiency Syndromes (1999). 53: 420-2. PMID 20190591 DOI: 10.1097/Qai.0B013E3181B7220F  0.475
2010 Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. The Journal of Infectious Diseases. 201: 662-71. PMID 20102271 DOI: 10.1086/650543  0.435
2010 Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 50: 416-25. PMID 20043752 DOI: 10.1086/649884  0.46
2009 Schackman BR, Dastur Z, Rubin DS, Berger J, Camhi E, Netherland J, Ni Q, Finkelstein R. Feasibility of using audio computer-assisted self-interview (ACASI) screening in routine HIV care. Aids Care. 21: 992-9. PMID 20024755 DOI: 10.1080/09540120802657506  0.409
2009 Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, Paltiel AD, Freedberg KA. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 49: 1570-8. PMID 19845472 DOI: 10.1086/644772  0.615
2009 Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 48: 806-15. PMID 19193111 DOI: 10.1086/597095  0.503
2008 Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. Aids (London, England). 22: 2025-33. PMID 18784465 DOI: 10.1097/Qad.0B013E3283103Ce6  0.463
2008 Schackman BR, Teixeira PA, Weitzman G, Mushlin AI, Jacobson IM. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Medical Decision Making : An International Journal of the Society For Medical Decision Making. 28: 233-42. PMID 18349430 DOI: 10.1177/0272989X07311753  0.361
2008 Teixeira PA, Schackman BR. Can urban methadone patients complete health utility assessments? Patient Education and Counseling. 71: 302-7. PMID 18314295 DOI: 10.1016/J.Pec.2008.01.010  0.328
2008 Koenig SP, Riviere C, Leger P, Severe P, Atwood S, Fitzgerald DW, Pape JW, Schackman BR. The cost of antiretroviral therapy in Haiti. Cost Effectiveness and Resource Allocation : C/E. 6: 3. PMID 18275615 DOI: 10.1186/1478-7547-6-3  0.356
2008 Schackman BR, Dastur Z, Ni Q, Callahan MA, Berger J, Rubin DS. Sexually active HIV-positive patients frequently report never using condoms in audio computer-assisted self-interviews conducted at routine clinical visits. Aids Patient Care and Stds. 22: 123-9. PMID 18260803 DOI: 10.1089/apc.2007.0037  0.313
2007 Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. Journal of Acquired Immune Deficiency Syndromes (1999). 46: 547-54. PMID 18193496 DOI: 10.1097/Qai.0B013E31815Ac499  0.329
2007 Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 45: 1062-70. PMID 17879926 DOI: 10.1086/521933  0.583
2007 Schackman BR, Neukermans CP, Fontain SN, Nolte C, Joseph P, Pape JW, Fitzgerald DW. Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. Plos Medicine. 4: e183. PMID 17535105 DOI: 10.1371/Journal.Pmed.0040183  0.436
2007 Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Aids (London, England). 21: 813-23. PMID 17415036 DOI: 10.1097/Qad.0B013E32805E8753  0.484
2007 Schackman BR, Teixeira PA, Beeder AB. Offers of hepatitis C care do not lead to treatment. Journal of Urban Health : Bulletin of the New York Academy of Medicine. 84: 455-8. PMID 17394085 DOI: 10.1007/S11524-007-9180-8  0.371
2006 Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Annals of Internal Medicine. 145: 797-806. PMID 17146064 DOI: 10.7326/0003-4819-145-11-200612050-00004  0.621
2006 Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999). 43: S113-8. PMID 17133193 DOI: 10.1097/01.Qai.0000248334.52072.25  0.609
2006 Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 43: S247-53. PMID 17109311 DOI: 10.1086/508190  0.382
2006 Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR, Moore RD, Freedberg KA. The lifetime cost of current human immunodeficiency virus care in the United States. Medical Care. 44: 990-7. PMID 17063130 DOI: 10.1097/01.Mlr.0000228021.89490.2A  0.584
2006 Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Jama. 296: 769-81. PMID 16905783 DOI: 10.1001/Jama.296.7.769  0.448
2006 Joseph P, Schackman BR, Horwitz R, Nerette S, Verdier RI, Dorsainvil D, Theodore H, Ascensio M, Henrys K, Wright PF, Johnson W, Pape JW, Fitzgerald DW. The use of an educational video during informed consent in an HIV clinical trial in Haiti. Journal of Acquired Immune Deficiency Syndromes (1999). 42: 588-91. PMID 16837867 DOI: 10.1097/01.Qai.0000229998.59869.05  0.393
2006 Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The survival benefits of AIDS treatment in the United States. The Journal of Infectious Diseases. 194: 11-9. PMID 16741877 DOI: 10.1086/505147  0.517
2006 Mrus JM, Schackman BR, Wu AW, Freedberg KA, Tsevat J, Yi MS, Zackin R. Variations in self-rated health among patients with HIV infection. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 15: 503-14. PMID 16547789 DOI: 10.1007/S11136-005-1946-4  0.484
2005 Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. Health Care Financing Review. 26: 67-80. PMID 17288069  0.572
2005 Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L, Ciccarone D, Hanna BS, Ritchie E, Hirschhorn LR, Mannheimer S, Moore RD, Van Devanter N, Alavarez R, Dougherty J, Agins B, et al. The cost of HIV medication adherence support interventions: Results of a cross-site evaluation Aids Care - Psychological and Socio-Medical Aspects of Aids/Hiv. 17: 927-937. PMID 16265786 DOI: 10.1080/09540120500100635  0.373
2005 Stone PW, Schackman BR, Neukermans CP, Olchanski N, Greenberg D, Rosen AB, Neumann PJ. A synthesis of cost-utility analysis literature in infectious disease. The Lancet. Infectious Diseases. 5: 383-91. PMID 15919624 DOI: 10.1016/S1473-3099(05)70142-0  0.325
2004 Schackman BR, Oneda K, Goldie SJ. The cost-effectiveness of elective Cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. Aids (London, England). 18: 1827-34. PMID 15316344 DOI: 10.1097/00002030-200409030-00012  0.445
2004 Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. The New England Journal of Medicine. 350: 1850-61. PMID 15115831 DOI: 10.1056/Nejmoa031772  0.457
2003 Krabbe PFM, Adang EMM, Stalmeier PFM, Schackman BR, Brazier J, Weinstein MC. Letter to the editor (multiple letters) Medical Decision Making. 23: 542-543. DOI: 10.1177/0272989X03236010  0.32
2002 Schackman BR, Freedberg KA, Weinstein MC, Sax PE, Losina E, Zhang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Archives of Internal Medicine. 162: 2478-86. PMID 12437408 DOI: 10.1001/Archinte.162.21.2478  0.63
2002 Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 22: 27-38. PMID 11833663 DOI: 10.1177/0272989X0202200103  0.602
2001 Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. American Journal of Public Health. 91: 1456-63. PMID 11527782 DOI: 10.2105/Ajph.91.9.1456  0.615
2001 Schackman B, Goldie S, Freedberg K, Losina E, Brazier J, Weinstein M. PID6: HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? Value in Health. 4: 130. DOI: 10.1046/J.1524-4733.2001.40202-164.X  0.631
Show low-probability matches.